140 related articles for article (PubMed ID: 38252675)
1. Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.
Grunst MW; Gil HM; Grandea AG; Snow BJ; Andrabi R; Nedellec R; Burton I; Clark NM; Janaka SK; Keles NK; Moriarty RV; Weiler AM; Capuano S; Fennessey CM; Friedrich TC; O'Connor SL; O'Connor DH; Broman AT; Keele BF; Lifson JD; Hangartner L; Burton DR; Evans DT
PLoS Pathog; 2024 Jan; 20(1):e1011819. PubMed ID: 38252675
[TBL] [Abstract][Full Text] [Related]
2. Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIV
von Bredow B; Andrabi R; Grunst M; Grandea AG; Le K; Song G; Berndsen ZT; Porter K; Pallesen J; Ward AB; Burton DR; Evans DT
mBio; 2019 Jul; 10(4):. PubMed ID: 31266872
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein.
Grunst MW; Ladd RA; Clark NM; Gil HM; Klenchin VA; Mason R; Franchini G; Roederer M; Evans DT
PLoS Pathog; 2023 May; 19(5):e1011407. PubMed ID: 37253062
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
[TBL] [Abstract][Full Text] [Related]
5. Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys.
Nguyen QN; Martinez DR; Himes JE; Whitney Edwards R; Han Q; Kumar A; Mangan R; Nicely NI; Xie G; Vandergrift N; Shen X; Pollara J; Permar SR
Retrovirology; 2018 Mar; 15(1):24. PubMed ID: 29523166
[TBL] [Abstract][Full Text] [Related]
6. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
[TBL] [Abstract][Full Text] [Related]
7. Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge.
Tuero I; Mohanram V; Musich T; Miller L; Vargas-Inchaustegui DA; Demberg T; Venzon D; Kalisz I; Kalyanaraman VS; Pal R; Ferrari MG; LaBranche C; Montefiori DC; Rao M; Vaccari M; Franchini G; Barnett SW; Robert-Guroff M
PLoS Pathog; 2015 Aug; 11(8):e1005101. PubMed ID: 26267144
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.
Florese RH; Van Rompay KK; Aldrich K; Forthal DN; Landucci G; Mahalanabis M; Haigwood N; Venzon D; Kalyanaraman VS; Marthas ML; Robert-Guroff M
J Immunol; 2006 Sep; 177(6):4028-36. PubMed ID: 16951366
[TBL] [Abstract][Full Text] [Related]
9. Control of Heterologous Simian Immunodeficiency Virus SIV
Singh S; Ramírez-Salazar EG; Doueiri R; Valentin A; Rosati M; Hu X; Keele BF; Shen X; Tomaras GD; Ferrari G; LaBranche C; Montefiori DC; Das J; Alter G; Trinh HV; Hamlin C; Rao M; Dayton F; Bear J; Chowdhury B; Alicea C; Lifson JD; Broderick KE; Sardesai NY; Sivananthan SJ; Fox CB; Reed SG; Venzon DJ; Hirsch VM; Pavlakis GN; Felber BK
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793957
[TBL] [Abstract][Full Text] [Related]
10. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
[TBL] [Abstract][Full Text] [Related]
11. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Xiao P; Zhao J; Patterson LJ; Brocca-Cofano E; Venzon D; Kozlowski PA; Hidajat R; Demberg T; Robert-Guroff M
J Virol; 2010 Jul; 84(14):7161-73. PubMed ID: 20444898
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
[TBL] [Abstract][Full Text] [Related]
13. Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques.
Pedreño-Lopez N; Rosen BC; Flores WJ; Gorman MJ; Voigt TB; Ricciardi MJ; Crosno K; Weisgrau KL; Parks CL; Lifson JD; Alter G; Rakasz EG; Magnani DM; Martins MA; Watkins DI
Front Immunol; 2021; 12():657424. PubMed ID: 33796119
[TBL] [Abstract][Full Text] [Related]
14. Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.
Nakane T; Nomura T; Shi S; Nakamura M; Naruse TK; Kimura A; Matano T; Yamamoto H
PLoS One; 2013; 8(9):e73453. PubMed ID: 24039947
[TBL] [Abstract][Full Text] [Related]
15. Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.
Rybarczyk BJ; Montefiori D; Johnson PR; West A; Johnston RE; Swanstrom R
J Virol; 2004 Apr; 78(7):3561-71. PubMed ID: 15016879
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
[TBL] [Abstract][Full Text] [Related]
17. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.
Alpert MD; Heyer LN; Williams DE; Harvey JD; Greenough T; Allhorn M; Evans DT
J Virol; 2012 Nov; 86(22):12039-52. PubMed ID: 22933282
[TBL] [Abstract][Full Text] [Related]
18. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
[TBL] [Abstract][Full Text] [Related]
19. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
[TBL] [Abstract][Full Text] [Related]
20. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML
J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
